Cellular Senescence in Osteoarthritis Pathology

Osteoarthritis is a chronic joint disorder characterised by progressive loss of cartilage integrity, subchondral bone remodelling and synovial inflammation. Central to its pathogenesis is the accumulation of senescent cells—particularly chondrocytes—that enter a state of permanent growth arrest yet remain metabolically active. These cells secrete a complex mix of pro-inflammatory cytokines, proteases and growth factors known as the senescence-associated secretory phenotype (SASP), which amplifies matrix degradation and local inflammation. Age, mechanical stress and oxidative damage converge on pathways such as p16INK4a/Rb, NF-κB and MAPK signalling, driving senescence across multiple joint tissues including cartilage, subchondral bone, synovium and infrapatellar fat pad. Emerging evidence also implicates DNA damage sensors and innate immune cascades—such as cGAS–STING—in orchestrating senescence and inflammation. Given the global burden of osteoarthritis and its limited treatment options, interventions that selectively eliminate or modulate senescent cells offer a promising route to preserve joint function and promote regeneration.

Research from Nature Portfolio

Recent studies have revealed that deficiency of myosin light chain 3 in chondrocytes enhances clathrin-mediated endocytosis and aberrant Notch signalling, thereby accelerating cellular senescence and osteoarthritic progression in mouse models. Pharmacological blockade of this endocytic–Notch axis mitigated senescence markers and preserved cartilage integrity, pointing to cell-internalisation pathways as novel therapeutic targets. In parallel, overexpression of the histone deacetylase Sirtuin 6 in articular chondrocytes was shown to suppress NF-κB-mediated inflammatory responses and reduce senescence-associated features, resulting in marked protection against cartilage degeneration in murine osteoarthritis.

Cellular Senescence in Osteoarthritis Pathology publication trend

The graph below shows the total number of articles in cellular senescence in osteoarthritis pathology across all publications each year (not limited to Nature Index journals).

Technical terms

Cellular senescence: A state of irreversible cell cycle arrest accompanied by metabolic activity and secretion of inflammatory factors.

Senescence-associated secretory phenotype (SASP): The array of cytokines, proteases and growth modulators secreted by senescent cells that promote inflammation and tissue remodelling.

Chondrocyte: A specialised cell responsible for synthesising and maintaining the extracellular matrix of articular cartilage.

Senolytic: An agent that selectively induces death of senescent cells to alleviate their detrimental effects.

Clathrin-mediated endocytosis: A cellular process for internalising extracellular molecules via vesicles coated with clathrin protein.

Efferocytosis: The clearance of apoptotic cells by phagocytic cells, critical for tissue homeostasis and resolution of inflammation.

References

1. Cellular senescence in osteoarthritis pathology. Aging Cell (2017).
2. STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-κB signaling pathway. Cell Death & Disease (2021).
3. MYL3 protects chondrocytes from senescence by inhibiting clathrin-mediated endocytosis and activating of Notch signaling. Nature Communications (2023).
4. Overexpression of Sirtuin 6 suppresses cellular senescence and NF-κB mediated inflammatory responses in osteoarthritis development. Scientific Reports (2015).
5. Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis. Bone Research (2024).
6. Novel strategy of senescence elimination via toxicity-exempted kinome perturbations by nanoliposome-based thermosensitive hydrogel for osteoarthritis therapy. Advanced Composites and Hybrid Materials (2023).
7. In Situ Remodeling of Efferocytosis via Lesion‐Localized Microspheres to Reverse Cartilage Senescence. Advanced Science (2024).